Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Apr
27
Today In Oncology
Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564
Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting
Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy
Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care
Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside